Gliwice, Poland Clinical Trials

A listing of Gliwice, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
Featured trial
Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and/or Cancer

The University of Tennessee Health Science Center in Memphis, TN has a research opportunity for people to participate in the study: Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and Cancer. Specifically, they are looking for individuals over the age of 60 for 1 of 3 groups: (1) those …

primary cancer
AIDS
Online studies
cancer
University of Tennessee Health Science Center
(online study) Contact site
  • 41 views
  • 28 Sep, 2022
  • 1 location
  • Online study
Featured trial
ARE YOU CARING FOR A LOVED ONE WITH DEMENTIA OR MCI?

You may be eligible to participate in a research study evaluating the effects of a new in-hometechnology system for caregivers of people with dementia or mild cognitive impairment. Thestudy is being conducted by Dr. Robert Levenson (University of California, Berkeley,Department of Psychology) and Gene Wang (People Power Company of Care …

Accepts healthy volunteers
dementia
Online studies
mild cognitive impairment
alzheimer's disease
University of California, Berkeley
(online study) Contact site
  • 48 views
  • 05 Dec, 2022
  • 1 location
  • Online study
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Nemocnice AGEL Novy Jicin a.s.; Oddeleni radioterapie a onkologie
 (59.8 away) Contact site
  • 21 views
  • 15 Oct, 2022
  • +653 other locations
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.

Clinhouse Centrum Medyczne
 (5.5 away) Contact site
  • 494 views
  • 15 Oct, 2022
  • +107 other locations
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis. (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion through an interactive voice …

SPSK nr 1; Klinika Neurologii
 (5.5 away) Contact site
  • 0 views
  • 18 Oct, 2022
  • +144 other locations
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

teriflunomide
evobrutinib
aubagio
Research Site 261
 (4.5 away) Contact site
  • 0 views
  • 23 Oct, 2022
  • +88 other locations
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in …

cancer
adjuvant therapy
pembrolizumab
mk-3475
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Oddzial w Krakowie ( Site 0959)
 (57.6 away) Contact site
  • 117 views
  • 12 Oct, 2022
  • +124 other locations
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis (RELEASE MSS5)

This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in participants with multiple sclerosis (MS). LLMT-6 is defined as the average of the 6 individual …

Wielospecjalistyczne Centrum Medyczne Ibismed
 (5.5 away) Contact site
  • 0 views
  • 04 Oct, 2022
  • +17 other locations
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis

Novartis Investigative Site
 (7.5 away) Contact site
  • 0 views
  • 07 Oct, 2022
  • +46 other locations
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

progressive disease
panobinostat capsules
ruxolitinib tablets
panobinostat
ruxolitinib
Novartis Investigative Site
 (89.6 away) Contact site
  • 148 views
  • 15 Oct, 2022
  • +27 other locations